Literature DB >> 30235456

Incidence of Hypersensitivity Reactions During Hemodialysis.

Raquel Esteras1, Juan Martín-Navarro2, Gabriel Ledesma3, Raúl Fernández-Prado4, Gilda Carreño3, Melissa Cintra5, Ignacio Cidraque6, Ignacio Sanz7, Blanca Tarragón7, Simona Alexandru8, Mónica Milla9, Elena Astudillo10, Emilio Sánchez10, Sebastian Mas4, Rafael Díaz Tejeiro11, Alberto Ortiz4, Rafael Sánchez3, Emilio González-Parra4.   

Abstract

BACKGROUND/AIMS: A recent alert from Spanish health authorities warned of a higher incidence of reported hypersensitivity reactions to hemodialysis membranes with polysulfone, in the 2017 review of acute reactions to dialyzers found only published reports in the 21st century on polysulfone and its derivatives. The aim is to assess/evaluate the current incidence and characteristics of hypersensitivity reactions in hemodialysis patients.
METHODS: A retrospective multicentre study in 9 Spanish hospitals evaluated patients in whom a hypersensitivity reaction required a change in dialyzer membrane.
RESULTS: A total of 37 patients out of 1561 (2.37%) had hypersensitivity reactions and clinical, epidemiological and analytical data were available for 33 patients (2.11%). The membranes involved were polysulfone (n=23), polynephron (n=8), polyethersulfone (n=1) and polyacrylonitrile (n=1). This distribution reflected the frequency of use of membranes in the participating dialysis units. The reactions were described as type A in 18 cases and type B in 15 cases. There were no significant differences between the two types in clinical symptoms, the composition of the membrane involved, the method of sterilization, the season, or the time during the session in which they occurred. The most frequent symptom was dyspnea/breathlessness (64% of reactions). Eosinophilia was common (74%). 54% of the reactions occurred within the first 30 minutes of hemodialysis, 64% occurred during the first year of dialysis, and 54% required discontinuation of dialysis session. Cellulose triacetate was used as an alternative dialyzer in 78% of the cases.
CONCLUSION: The incidence of hypersensitivity reactions was in the range found in reports from 20 years ago and is observed associated with synthetic membranes, not just polysulfones. Cellulose triacetate appears to be a good alternative for these patients.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Acute reaction; Allergic reaction; Dialyzer; Hemodialysis; Membrane; Polynephron; Polysulfone

Mesh:

Substances:

Year:  2018        PMID: 30235456     DOI: 10.1159/000493662

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  5 in total

1.  Performance and Hemocompatibility of a Novel Polysulfone Dialyzer: A Randomized Controlled Trial.

Authors:  Götz Ehlerding; Ansgar Erlenkötter; Adelheid Gauly; Bettina Griesshaber; James Kennedy; Lena Rauber; Wolfgang Ries; Hans Schmidt-Gürtler; Manuela Stauss-Grabo; Stephan Wagner; Adam M Zawada; Sebastian Zschätzsch; Manuela Kempkes-Koch
Journal:  Kidney360       Date:  2021-04-07

2.  The removal capacity of asymmetric cellulose triacetate during post-dilution online hemodiafiltration.

Authors:  Alba Santos; Nicolás Macías; Leonidas Cruzado; Almudena Vega
Journal:  Kidney Res Clin Pract       Date:  2021-04-14

Review 3.  Blood-incompatibility in haemodialysis: alleviating inflammation and effects of coagulation.

Authors:  Sudhir K Bowry; Fatih Kircelli; Rainer Himmele; Sagar U Nigwekar
Journal:  Clin Kidney J       Date:  2021-12-27

4.  Cardiopulmonary arrest caused by nafamostat mesylate during hemodialysis.

Authors:  Nobuki Shioya; Nozomu Inoue; Hiroki Sato; Motoko Iwahara; Tomohiro Sato; Yuki Tsukamoto; Yuki Naito; Kohji Hazama; Yasuo Shichinohe
Journal:  Clin Case Rep       Date:  2022-07-25

5.  Older Age and High Serum Ferritin Levels Associated With the Risk of Chronic Cytopenia in Hemodialysis Patients.

Authors:  Yu-Ting Lee; Wei-Yu Wang; Chin-Ho Kuo; Ming-Yang Lee; Yin-Che Lu; Chih-Yen Hsiao; Yueh-Han Hsu; Peir-Haur Hung
Journal:  Front Med (Lausanne)       Date:  2020-10-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.